News from european hematology association A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

16 Jun, 2018, 07:30 BST European Hematology Association: iNNOVATE Study: Ibrutinib Plus Rituximab for Patients With Waldenström's Macroglobulinemia

Waldenström's Macroglobulinemia (WM) is a rare type of blood cancer. Since WM is rare, it is difficult to conduct large clinical studies and...


16 Jun, 2018, 07:30 BST European Hematology Association: Answering the Unmet Need in One of the Most Common Types of Lymphoma: It's as Simple as A-D-C

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Unfortunately, 40% of patients will relapse after or not...


16 Jun, 2018, 07:30 BST European Hematology Association: A New Anti-CD22 CAR-T Immunotherapy Saved Life of Children With Leukemia

B acute lymphoblastic leukemia (B-ALL) is a fatal blood cell tumor that is usually treated with chemotherapy or allogeneic hematopoietic stem cell...


15 Jun, 2018, 07:30 BST European Hematology Association: First-in-Human CLL1-CD33 Compound CAR T Cells as a Two-Pronged Approach for the Treatment of Refractory Acute Myeloid Leukemia

Purpose: To firstly study the anti-leukemic activity of the CLL1-CD33 compound CAR in vitro and in vivo and consequently offer opportunities to the...


15 Jun, 2018, 07:30 BST European Hematology Association: Overall Survival Benefit of Obinutuzumab Over Rituximab When Combined With Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Comorbidities

Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody that is able to attack chronic lymphocytic leukemia (CLL) by binding and...


15 Jun, 2018, 07:30 BST European Hematology Association: Iron: a double-edged Sword in Inflammation

Iron is a vital element required for several biologic functions, first of all oxygen delivery to tissues, which occurs through the iron-containing...


15 Jun, 2018, 07:30 BST European Hematology Association: Is RELEVANCE Relevant? Results of the Phase III Study of R2 vs R-chemo in First-line Follicular Lymphoma

Chemoimmunotherapy (R-chemo) induction followed by rituximab maintenance is the standard of care in previously untreated, symptomatic follicular...


15 Jun, 2018, 07:30 BST European Hematology Association: Update on bb2121, a Promising Therapy for Patients with Heavily Pre-treated Relapsed/Refractory Multiple Myeloma

The anti-BCMA CAR T cell therapy bb2121 has demonstrated substantial activity in heavily pre-treated patients with multiple myeloma (MM). Updated...


15 Jun, 2018, 07:30 BST European Hematology Association: AHL2011: Outstanding Disease Control With a Minimized BEACOPP Exposure and Toxicity in Patients With Advanced Hodgkin Lymphoma

Six cycles of BEACOPP provide a better long-term disease control than ABVD in advanced Hodgkin lymphoma but is associated to more frequent...


14 Jun, 2018, 14:25 BST European Hematologists to Discuss Breakthroughs in Blood Disorders in Stockholm, Sweden on June 14-17, 2018

More than 11,000 participants from around the world are expected at the upcoming 23rd Congress of the European Hematology Association (EHA) at the...


24 Jun, 2017, 07:30 BST European Hematology Association: Clinical and Biologic Covariates of Outcomes in ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Patients with Refractory Aggressive non-Hodgkin Lymphoma (NHL)

Outcomes for patients with refractory, aggressive non-Hodgkin lymphoma (NHL) are poor with current therapies. Axicabtagene ciloleucel (axi-cel) is an ...


24 Jun, 2017, 07:30 BST European Hematology Association: Early Metabolic Response Determination by FDG-PET Allows Substantial Reduction of Chemotherapy and its Toxicity in Patients with Advanced Stage Hodgkin Lymphoma: the GHSG HD18 Study

Hodgkin lymphoma is the most common malignancy of young adults. Intensive chemotherapy with eight or six cycles of eBEACOPP is very effective in...


24 Jun, 2017, 07:30 BST European Hematology Association: Global Trial of the Efficacy and Safety of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma: An Interim Analysis of the JULIET Study

CTL019 consists of genetically engineered autologous T cells expressing a chimeric antigen receptor (CAR). Results from a prior single-center phase 2 ...


24 Jun, 2017, 07:30 BST European Hematology Association: Multicenter Open-label Phase 2 Study of ibrutinib in Chronic Graft Versus Host Disease (cGVHD) After Failure of Corticosteroids

Ibrutinib: A promising new treatment for chronic graft versus host disease. Chronic graft versus host disease (cGVHD) is a serious and...


24 Jun, 2017, 07:30 BST HARMONY: European Network of Excellence in Hematology and Big Data to Present New Bench-To-Bedside Projects During the 22nd Annual Congress of the European Hematology Association

Providing the right treatment in time for patients with hematologic malignancies: that is the ambition of the HARMONY Alliance, European Network of...


24 Jun, 2017, 07:30 BST European Hematology Association: Bleeding or Clotting in Elderly Patients with Cancer-Associated Venous Thromboembolism: Which is Worse?

The risk of blood clots in the veins of the legs or the lungs, known as venous thrombosis (VTE) is higher in cancer patients, and so is the risk of...


23 Jun, 2017, 07:30 BST European Hematology Association: Treating Sickle Cell Disease and Beta-Thalassemia with CRISPR/Cas9 Gene Editing

Sickle Cell Disease and Beta-thalassemia are two severe diseases that are caused by defects in the beta-globin protein in hemoglobin, present in red...


23 Jun, 2017, 07:30 BST European Hematology Association: The More the T-lymphocytes Differ, the More Effectively They Fight Against Leukemia

Adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia (r/r ALL) have a poor prognosis despite intense salvage treatments....


23 Jun, 2017, 07:30 BST European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL

Cerdulatinib is an oral, dual Syk-JAK inhibitor with a unique mechanism of action. It inhibits two key signaling pathways that promote cancer cell...


23 Jun, 2017, 07:30 BST European Hematology Association: Shedding New Light on the Prevention of Platelet Storage Lesion

Hemorrhagic and thrombocytopenic patients require platelet transfusion to prevent or treat bleeding. Cold storage of platelets results in complex...


23 Jun, 2017, 07:30 BST European Hematology Association: Delayed Exposure to Common Infections Causes Acute Leukemia of Childhood

Acute leukemia is the most common cancer in childhood and the incidence is increasing especially in socio economic advanced countries. Infection as a ...


22 Jun, 2017, 07:30 BST European Hematology Association Publishes New Journal With Wolters Kluwer

The European Hematology Association, the largest Europe-based association of hematologists, launched its new journal HemaSphere with publisher...


19 Jun, 2017, 15:42 BST Hematologists to Discuss Breakthroughs in Blood Disorders in Madrid

More than 10,000 hematology professionals from around the world will gather and discuss the latest developments in hematology research and clinical...


14 Mar, 2017, 17:27 GMT EuroBloodNet Aims for Better Care for Patients with Rare Blood Disorders

Patients suffering from rare blood disorders will benefit from networks of excellence across the European Member States. At the third conference on...


19 Jan, 2017, 14:00 GMT HARMONY: Better Care of Patients with Hematologic Malignancies Kicked Off!

Attended by 150 participants from 18 countries the HARMONY project successfully kicked off with a two-day meeting on January 16 and 17. HARMONY is a...